Topics

Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal cancer

11:06 EST 9 Nov 2019 | 2 Minute Medicine

1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single agent. 2. Doublet therapy with encorafenib-cetuximab […]
Source: 2 Minute Medicine

Original Article: Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal cancer

NEXT ARTICLE

More From BioPortfolio on "Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal cancer"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...